CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

BACKGROUND: Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Brooks, Jennifer D., Comen, Elizabeth A., Reiner, Anne S., Orlow, Irene, Leong, Siok F., Liang, Xiaolin, Mellemkjær, Lene, Knight, Julia A., Lynch, Charles F., John, Esther M., Bernstein, Leslie, Woods, Meghan, Doody, David R., Malone, Kathleen E., Bernstein, Jonine L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6288916/
https://ncbi.nlm.nih.gov/pubmed/30526633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-1083-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados